INBX Inhibrx Biosciences Inc.

  1. Stocks
  2. Healthcare
  3. NASDAQ: INBX

Price (delayed)

$17.28

Market cap

$250.14M

P/E Ratio

N/A

Dividend/share

N/A

EPS

N/A

Enterprise value

$25.45M

Highlights
The debt has plunged by 99% from the previous quarter
The quick ratio has soared by 64% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Peers: NVAX NVCR NBIX

Key stats

What are the main financial stats of INBX
Market
Shares outstanding
14.48M
Market cap
$250.14M
Enterprise value
$25.45M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
1.05
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
N/A
EBIT
N/A
EBITDA
N/A
Free cash flow
N/A
Per share
EPS
N/A
Free cash flow per share
N/A
Book value per share
$16.39
Revenue per share
N/A
TBVPS
$17.68
Balance sheet
Total assets
$258.42M
Total liabilities
$39.05M
Debt
$2.17M
Equity
$219.37M
Working capital
$203.01M
Liquidity
Debt to equity
0.01
Current ratio
6.2
Quick ratio
5.84
Net debt/EBITDA
N/A
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
N/A
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
N/A
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

INBX stock price

How has the Inhibrx Biosciences stock price performed over time
Intraday
0.35%
1 week
15.2%
1 month
38.68%
1 year
N/A
YTD
N/A
QTD
21.95%

Financial performance

How have Inhibrx Biosciences's revenue and profit performed over time
Revenue
N/A
Gross profit
N/A
Operating income
N/A
Net income
N/A
Gross margin
N/A
Net margin
N/A

Growth

What is Inhibrx Biosciences's growth rate over time

Valuation

What is Inhibrx Biosciences stock price valuation
P/E
N/A
P/B
1.05
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A

Efficiency

How efficient is Inhibrx Biosciences business performance

Dividends

What is INBX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for INBX.

Financial health

How did Inhibrx Biosciences financials performed over time
The total liabilities has plunged by 86% from the previous quarter
The quick ratio has soared by 64% from the previous quarter
The debt is 99% less than the equity
The debt to equity has plunged by 100% from the previous quarter
The debt has plunged by 99% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified. Data from and Sharadar.